Short Interest in UCB SA (OTCMKTS:UCBJY) Increases By 133.3%

UCB SA (OTCMKTS:UCBJY) was the target of a significant growth in short interest in September. As of September 30th, there was short interest totalling 700 shares, a growth of 133.3% from the September 15th total of 300 shares. Based on an average daily trading volume, of 11,300 shares, the days-to-cover ratio is presently 0.1 days.

UCB Stock Performance

Shares of OTCMKTS:UCBJY opened at $91.70 on Friday. The company has a fifty day simple moving average of $88.80 and a 200 day simple moving average of $76.66. UCB has a 12-month low of $34.85 and a 12-month high of $94.16.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.